Caraco Pharmaceutical Laboratories Ltd Watch

from 8-K 3 pages First Amendment to Distribution and Sale Agreement Between Caraco Pharmaceutical Laboratories Ltd and Sun Pharmaceutical Industries Limited

from 8-K 3 pages Second Amendment to Agreement Between Caraco Pharmaceutical Laboratories Ltd and Sun Pharmaceutical Industries Limited 1

from 8-K 3 pages First Amendment to Agreement Between Caraco Pharmaceutical Laboratories Ltd and Sun Pharmaceutical Industries Limited

from 10-Q 7 pages Form of Grant of Employee Stock Option Date

from 10-Q 6 pages Form of Grant of Independent Director’s Stock Option Date

from 10-Q 15 pages Indemnification Agreement

from 10-Q 26 pages Agreement

from 10-Q 4 pages Employment Agreement

from 10-Q 5 pages Separation Agreement and Release of All Claims

from 10-Q 17 pages This Exhibit Has Been Redacted and Is the Subject of a Confidential Treatment Request. Redacted Material Is Marked With [* * *] and Has Been Filed Separately With the Securities and Exchange Commission. Settlement Agreement

from 10-K 1 page Summary of Oral Agreements Between Caraco and Sun Pharmaceutical Industries Limited With Respect to Certain Raw Materials and Formulations and the Acquisition of Machinery and Equipment

from 8-K ~50 pages Distribution and Sale Agreement Between Caraco Pharmaceutical Laboratories Ltd and Sun Pharmaceutical Industries Limited

from 8-K/A 19 pages 1. License to Market of Products by Sun to Caraco. 1.1 Offer of the Products by Sun and Acceptance by Caraco. the Generic Pharmaceutical Products Which Require Andas May Be Offered From Time to Time for Inclusion Under This Agreement by Sun to Caraco for Marketing, Distributing, Selling, Using,

from 10-Q 5 pages Grantee Number of Restricted Shares Daniel H. Movens

from 10-Q 9 pages Grantee Number of Option Shares Daniel H. Movens

from 8-K 16 pages Agreement Between Caraco Pharmaceutical Laboratories Ltd and Sun Pharmaceutical Industries Limited

from 10-K 7 pages Form of Grant of Employee Stock Option Date

from 10-Q 17 pages Security Agreement

from 8-K 1 page Jitendra N. Doshi, the CFO and COO, Receive an Annual Salary of $200,000 (For Fiscal Year 2006 and Effective as of April 1, 2005), and Be Eligible for a Performance Bonus of Up to 30% of Salary Based on Achievement of Various Criteria During Fiscal Year 2006. Robert Kurkiewicz, the Senior Vice President-Technical Receive an Annual Salary of $152,500 (For Fiscal Year 2006 and Effective as of April 1, 2005), and Be Eligible for a Performance Bonus of Up to 23% of Salary Based on Achievement of Various Criteria During Fiscal Year 2006. Gurpartap Singh Sachdeva, the Vice President – Sales & Marketing, Receive an Annual Salary of $175,500 (For Fiscal Year 2006 and Effective as of April 1, 2005), and Be Eligible for a Performance Bonus of Up to 25% of Salary Based on Achievement of Various Criteria During Fiscal Year 2006. 3

from 10-K/A 3 pages Confidentiality and Non-Competition Agreement